Skip to main content
SpringerLink
Log in

Botulinumtoxin als Teil einer integrierten Behandlung

Update 2009

Botulinum toxin as part of an integrative therapeutic approach

Update 2009

  • Leitthema
  • Published:
Monatsschrift Kinderheilkunde Aims and scope Submit manuscript

Zusammenfassung

Seit dem letzten interdisziplinären deutschsprachigen Konsensus Botulinumtoxin für Kinder mit Zerebralparesen („cerebral palsy“, CP) im Jahr 2007 hat sich das Fächer übergreifende, integrative Behandlungskonzept für die Zerebralparesen zusehends etabliert. Neuropädiater, Sozialpädiater, Kinderorthopäden, Orthopädiemechaniker und Therapeuten konnten im Juni 2009 in Freiburg den ersten interdisziplinären CP-Kongress ausrichten, welcher bei allen Disziplinen eine große Resonanz erfuhr. Neben den bereits in den anderen Beiträgen dieses Heftes beschriebenen Fortschritten gibt es bei 4 Themen in der Behandlung mit Botulinumtoxin (BoNT) neue Erkenntnisse. 1. „Sicherheit der Behandlung mit Botulinumtoxin“, 2. „Paradigmenwechsel Aktivität: BoNT als Modulator des muskulären Ungleichgewichtes“, 3. „Zulassung neuer Präparate“, 4. „Botulinumtoxin im zeitlichen Verlauf“. Auf diese 4 Themen soll im vorliegenden Beitrag eingegangen werden. Die hier vorgestellten Inhalte stellen einen Auszug aus dem aktualisierten europäischen Konsensus zur Behandlung mit Botulinumtoxin für Kinder mit CP 2009 dar (in press) und fassen diesen mit dem im Sommer dieses Jahres publizierten grafikgestützten Konsensus für die Behandlung von Bewegungsstörungen bei Kindern mit bilateraler spastischer Zerebralparese zusammen.

Abstract

After the publication of the interdisciplinary German consensus on botulinum toxin (BoNT) and the treatment of gross motor function disorders in children with cerebral palsy (CP) in 2007, the integrative therapeutic concept has progressively been incorporated into the clinical routine. Paediatric neurologists, social paediatricians, paediatric orthopaedic surgeons, orthoptists, and therapists gathered to hold the first interdisciplinary CP conference of the German-speaking countries in June 2009 (Freiburg, Germany), which received great feedback. Besides the topics described in the preceding articles of this issue, four subjects regarding BoNT treatment in children with CP have (re)emerged: (1) the safety of BoNT treatment, (2) a paradigm shift to BoNT as a modulator of muscular imbalance, (3) newly approved BoNT preparations, and (4) the effect of BoNT treatment over the course of time. This review focuses on these four topics and tries to integrate the information on the basis of the updated European consensus 2009 (in press) and the graphics-supported consensus on the treatment of movement disorders in children with bilateral spastic CP, which was published in this journal in summer 2009.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Albavera-Hernandez C, Rodriguez JM, Idrovo AJ (2009) Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clin Rehabil 23(5):394–407

    Article  PubMed  Google Scholar 

  2. Autti-Ramo I, Suoranta J, Anttila H et al (2006) Effectiveness of upper and lower limb casting and orthoses in children with cerebral palsy: an overview of review articles. Am J Phys Med Rehabil 85(1):89–103

    Article  PubMed  Google Scholar 

  3. Berweck S, Lee S, Schroeder A, Heinen F (2005) Botulinumtoxin (BTX) – Biologisches Prinzip und Medikament interventioneller Neuropädiatrie. Monatsschr Kinderheilkd 153:379–393

    Article  Google Scholar 

  4. Berweck S, Schroeder AS, Huss K et al (2008) Safety of botulinum toxin treatment in children with cerebral palsy in correlation to GMFCS level. Neuropediatrics 39:5 PO71 DOI: 10.1055/s-0029-1215840:39

    Google Scholar 

  5. Blackmore AM, Boettcher-Hunt E, Jordan M, Chan MD (2007) A systematic review of the effects of casting on equinus in children with cerebral palsy: an evidence report of the AACPDM. Dev Med Child Neurol 49(10):781–790

    Article  CAS  PubMed  Google Scholar 

  6. Borggraefe I, Meyer-Heim A, Kumar A et al (2008) Improved gait parameters after robotic-assisted locomotor treadmill therapy in a 6-year-old child with cerebral palsy. Mov Disord 23(2):280–283

    Article  PubMed  Google Scholar 

  7. Borodic GE, Ferrante R (1992) Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 12(2):121–127

    CAS  PubMed  Google Scholar 

  8. Crowner BE, Racette BA (2008) Prospective study examining remote effects of botulinum toxin a in children with cerebral palsy. Pediatr Neurol 39(4):253–258

    Article  PubMed  Google Scholar 

  9. Crowner BE, Brunstrom JE, Racette BA (2007) Iatrogenic botulism due to therapeutic botulinum toxin A injection in a pediatric patient. Clin Neuropharmacol 30(5):310–313

    Article  PubMed  Google Scholar 

  10. De Paiva A, Meunier FA, Molgo J et al (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96(6):3200–3205

    Article  Google Scholar 

  11. Dong M, Yeh F, Tepp WH et al (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312(5773):592–596

    Article  CAS  PubMed  Google Scholar 

  12. Dressler D, Saberi FA, Barbosa ER (2005) Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 63(1):180–185

    PubMed  Google Scholar 

  13. European consensus (2009) Eur J Paediatr Neurol in press

  14. Food and Drug Administration (FDA) (2008) Follow-up to the February 8, 2008, early communication about an ongoing safety review of botox and botox cosmetic (botulinum toxin type A) and myobloc (botulinum toxin type B). FDA, Silver Spring, www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm143819.htm

  15. Gesellschaft für Neuropädiatrie (GNP), Arbeitsgemeinschaft der niedergelassenen Neuropädiater (AG-NNP), Deutsche Gesellschaft für Sozialpädiatrie und Jugendmedizin (DGSPJ), Arbeitskreis Infantile Cerebralparesen der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC), Deutsche Gesellschaft für Neurologische Rehabilitation (DGNR), Deutschsprachige Vereinigung für Kinderorthopädie und Arbeitskreis Botulinumtoxin der Deutschen Gesellschaft für Neurologie (AK-BoNT der DGN) (2007) Botulinumtoxin für Kinder mit Zerebralparesen: 10-Punkte-Tabelle, 2007 Ein interdisziplinärer deutscher Konsensus. Monatsschr Kinderheilkd 155(6):537–543

    Article  Google Scholar 

  16. Goldstein EM (2006) Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 21(3):189–192

    PubMed  Google Scholar 

  17. Graham HK (2001) Botulinum toxin type A management of spasticity in the context of orthopaedic surgery for children with spastic cerebral palsy. Eur J Neurol [Suppl 5] 8:30–39

    Google Scholar 

  18. Hassan SM, Jennekens FG, Veldman H (1995) Botulinum toxin-induced myopathy in the rat. Brain 118(Pt 2):533–545

    Article  PubMed  Google Scholar 

  19. Heinen F, Schroeder AS, Fietzek U, Berweck S (2006) When it comes to botulinum toxin, children and adults are not the same: multimuscle option for children with cerebral palsy. Mov Disord 21(11):2029–2030

    Article  PubMed  Google Scholar 

  20. Heinen F, Schröder AS, Döderlein L et al (2009) Grafikgestützter Konsensus für die Behandlung von Bewegungsstörungen bei Kindern mit bilateralen spastischen Zerebralparesen (BS-CP). Monatsschr Kinderheilkd 157:789–794

    Article  Google Scholar 

  21. Hoare BJ, Wasiak J, Imms C, Carey L (2007) Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsy. Cochrane Database Syst Rev 2:CD004149

    PubMed  Google Scholar 

  22. Howell K, Selber P, Graham HK, Reddihough D (2007) Botulinum neurotoxin A: an unusual systemic effect. J Paediatr Child Health 43(6):499–501

    Article  PubMed  Google Scholar 

  23. Huss K, Berweck S, Schroeder AS et al (2009) Interventional-neuropaediatric spectrum of treatments with botulinum neurotoxin type A, free of complexing proteins: effective and safe application – three exemplary cases. Abstracts of the 35th Annual Meeting of the Society of Neuropediatrics, Graz. Neuropaediatrics 39:5 DOI: 10.1055/s-0029-1215846

    Google Scholar 

  24. Jost WH, Kohl A, Brinkmann S, Comes G (2005) Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm 112(7):905–913

    Article  CAS  PubMed  Google Scholar 

  25. Kolaski K, Ajizian SJ, Passmore L et al (2008) Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population. Am J Phys Med Rehabil 87(7):556–566

    Article  PubMed  Google Scholar 

  26. Kuhnke N, Juenger H, Walther M et al (2008) Do patients with congenital hemiparesis and ipsilateral corticospinal projections respond differently to constraint-induced movement therapy? Dev Med Child Neurol 50(12):898–903

    Article  CAS  PubMed  Google Scholar 

  27. Meyer-Heim A, Ammann-Reiffer C, Schmartz A (2009) Improvement of walking abilities after robotic-assisted locomotion training in children with cerebral palsy. Arch Dis Child 94(8):615–620

    Article  CAS  PubMed  Google Scholar 

  28. Molenaers G, Eyssen M, Desloovere K et al (1999) A multilevel approach to botulinum toxin type A treatment of the (ilio)psoas in spasticity in cerebral palsy. Eur J Neurol [Suppl 4] 6:59–62

    Google Scholar 

  29. Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20(7):981–990

    Article  CAS  PubMed  Google Scholar 

  30. Naumann M, Albanese A, Heinen F et al (2006) Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol [Suppl 4] 13:35–40

    Google Scholar 

  31. Sakzewski L, Ziviani J, Boyd R (2009) Systematic review and meta-analysis of therapeutic management of upper-limb dysfunction in children with congenital hemiplegia. Pediatrics 123(6):e1111–e1122

    Article  PubMed  Google Scholar 

  32. Sanger TD, Delgado MR, Gaebler-Spira D et al (2003) Classification and definition of disorders causing hypertonia in childhood. Pediatrics 111(1):e89–e97

    Article  PubMed  Google Scholar 

  33. Schröder JM, Huffmann B, Braun V, Richter HP (1992) Spasmodic torticollis: severe compression neuropathy in rami dorsales of cervical nerves C1–6. Acta Neuropathol (Berl) 84(4):416–424

    Google Scholar 

  34. Schroeder AS, Ertl- Wagner B, Schröder J et al (2009) Botulinumtoxin im Muskel – in vivo Untersuchungen über zwei Jahre, bestätigt durch histopathologische Untersuchung des Muskels. In: Bundesarbeitsgemeinschaft Ärzte für Menschen mit geistiger oder mehrfacher Behinderung e.V. (Hrsg) Focus Cerebralparesen 1. Interdisziplinärer Kongress Neuropädiatrie, Sozialpädiatrie, Kinderorthopädie, Freiburg im Breisgau, 18.–20. Juni

  35. Schroeder AS, Ertl-Wagner B, Britsch S et al (2009) Muscle biopsy substantiates long-term MRI alterations one year after a single dose of botulinum toxin injected into the lateral gastrocnemius muscle of healthy volunteers. Mov Disord 24(10):1494–503

    Article  PubMed  Google Scholar 

  36. Simpson DM, Gracies JM, Graham HK et al (2008) Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70(19):1691–1698

    Article  CAS  PubMed  Google Scholar 

  37. Thilmann AF, Fellows SJ, Garms E (1991) The mechanism of spastic muscle hypertonus. Variation in reflex gain over the time course of spasticity. Brain 114(Pt 1A):233–244

    PubMed  Google Scholar 

  38. Willis AW, Crowner B, Brunstrom JE et al (2007) High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol 49(11):818–822

    Article  PubMed  Google Scholar 

  39. Wohlfarth K, Muller C, Sassin I et al (2007) Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Clin Neuropharmacol 30(2):86–94

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Der korrespondierende Autor hat in Kooperation zu der Firma Pharm Allergan, Ettlingen, Fortbildungen und/oder Referententätigkeit zum Themenkomplex „Cerebralparesen und Botulinumtoxin“ unternommen.

Author information

Authors and Affiliations

  1. Abteilung für Pädiatrische Neurologie, Entwicklungsneurologie und Sozialpädiatrie, Dr. von Haunersches Kinderspital, Ludwig-Maximilians-Universität München, Lindwurmstraße 4, 80337, München, Deutschland

    A.S. Schröder, K. Huß, S. Berweck & F. Heinen

Authors
  1. A.S. Schröder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Huß
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Berweck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Heinen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A.S. Schröder.

Zusatzmaterial online

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schröder, A., Huß, K., Berweck, S. et al. Botulinumtoxin als Teil einer integrierten Behandlung. Monatsschr Kinderheilkd 157, 1120–1127 (2009). https://doi.org/10.1007/s00112-009-2040-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00112-009-2040-8

Schlüsselwörter

Keywords

Search

Navigation